In one of the largest prospective trials evaluating the mTOR inhibitor, everolimus, in recurrent TET (thymoma and thymic carcinoma), five partial and one complete responses were noted in 51 patients (CR + PR =12%) with 3 partial responses occurring in the 32 patients with thymoma (10). This evidence concerns the gene MTOR and thymic carcinoma.